EA202190114A1 - Способы лечения clrn1-ассоциированной потери слуха и/или потери зрения - Google Patents
Способы лечения clrn1-ассоциированной потери слуха и/или потери зренияInfo
- Publication number
- EA202190114A1 EA202190114A1 EA202190114A EA202190114A EA202190114A1 EA 202190114 A1 EA202190114 A1 EA 202190114A1 EA 202190114 A EA202190114 A EA 202190114A EA 202190114 A EA202190114 A EA 202190114A EA 202190114 A1 EA202190114 A1 EA 202190114A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- loss
- treatment
- clrn1
- methods
- associated hearing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Abstract
В изобретении предложены композиции, которые содержат один вектор нуклеиновой кислоты или два разных вектора нуклеиновых кислот, и применение этих композиций для лечения потери слуха и/или потери зрения у субъекта.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862689660P | 2018-06-25 | 2018-06-25 | |
PCT/US2019/039030 WO2020005974A1 (en) | 2018-06-25 | 2019-06-25 | Methods of treating clrn1-associated hearing loss and/or vision loss |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190114A1 true EA202190114A1 (ru) | 2021-05-12 |
Family
ID=68985009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190114A EA202190114A1 (ru) | 2018-06-25 | 2019-06-25 | Способы лечения clrn1-ассоциированной потери слуха и/или потери зрения |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210277417A1 (ru) |
EP (1) | EP3824090A4 (ru) |
JP (2) | JP2021529519A (ru) |
KR (1) | KR20210057720A (ru) |
CN (1) | CN112639107A (ru) |
AU (1) | AU2019294603A1 (ru) |
BR (1) | BR112020026606A2 (ru) |
CA (1) | CA3104330A1 (ru) |
CL (1) | CL2020003346A1 (ru) |
EA (1) | EA202190114A1 (ru) |
IL (1) | IL279551A (ru) |
MX (1) | MX2020013628A (ru) |
SG (1) | SG11202012710WA (ru) |
WO (1) | WO2020005974A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3233522A1 (en) * | 2021-09-30 | 2023-04-06 | Katherine Diane GRIBBLE | Gene therapy delivery compositions and methods for treating hearing loss |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080016786A (ko) * | 2005-02-03 | 2008-02-22 | 주식회사 바이오텍 아이 | 당뇨병 치료용 조성물 및 당뇨병 치료 방법 |
ES2654205T3 (es) * | 2012-03-27 | 2018-02-12 | Curevac Ag | Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos |
CN102978284A (zh) * | 2012-11-19 | 2013-03-20 | 金子兵 | 一种筛查各类眼科遗传性疾病的基因芯片及其制备和使用方法 |
US10369231B2 (en) * | 2013-03-11 | 2019-08-06 | Fondazione Telethon | MiR-204 and miR-211 and uses thereof |
US11827680B2 (en) * | 2014-11-06 | 2023-11-28 | Case Western Reserve University | Compounds and methods of treating usher syndrome III |
US11167042B2 (en) * | 2015-12-11 | 2021-11-09 | Massachusetts Eye And Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
JP2019530737A (ja) * | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
-
2019
- 2019-06-25 EP EP19827048.0A patent/EP3824090A4/en active Pending
- 2019-06-25 EA EA202190114A patent/EA202190114A1/ru unknown
- 2019-06-25 AU AU2019294603A patent/AU2019294603A1/en active Pending
- 2019-06-25 MX MX2020013628A patent/MX2020013628A/es unknown
- 2019-06-25 CN CN201980055197.XA patent/CN112639107A/zh active Pending
- 2019-06-25 JP JP2020572414A patent/JP2021529519A/ja active Pending
- 2019-06-25 BR BR112020026606-0A patent/BR112020026606A2/pt unknown
- 2019-06-25 SG SG11202012710WA patent/SG11202012710WA/en unknown
- 2019-06-25 US US17/253,658 patent/US20210277417A1/en active Pending
- 2019-06-25 CA CA3104330A patent/CA3104330A1/en active Pending
- 2019-06-25 KR KR1020217002300A patent/KR20210057720A/ko active Search and Examination
- 2019-06-25 WO PCT/US2019/039030 patent/WO2020005974A1/en unknown
-
2020
- 2020-12-17 IL IL279551A patent/IL279551A/en unknown
- 2020-12-22 CL CL2020003346A patent/CL2020003346A1/es unknown
-
2023
- 2023-08-23 JP JP2023135405A patent/JP2023153320A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3824090A1 (en) | 2021-05-26 |
SG11202012710WA (en) | 2021-01-28 |
CA3104330A1 (en) | 2020-01-02 |
WO2020005974A1 (en) | 2020-01-02 |
MX2020013628A (es) | 2021-05-27 |
EP3824090A4 (en) | 2022-06-01 |
IL279551A (en) | 2021-01-31 |
JP2023153320A (ja) | 2023-10-17 |
JP2021529519A (ja) | 2021-11-04 |
KR20210057720A (ko) | 2021-05-21 |
AU2019294603A1 (en) | 2021-01-14 |
US20210277417A1 (en) | 2021-09-09 |
BR112020026606A2 (pt) | 2021-04-06 |
CL2020003346A1 (es) | 2021-05-14 |
CN112639107A (zh) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
MA44890A (fr) | Compositions comprenant des souches bactériennes | |
EP4219724A3 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
WO2018081648A3 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
MX2019006334A (es) | Anticuerpos antitau y métodos de uso. | |
EA201790532A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса | |
MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
EA202091995A1 (ru) | Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека | |
MX2017016518A (es) | Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo. | |
WO2017075173A3 (en) | Anti-factor d antibodies and conjugates | |
WO2017136450A3 (en) | Compounds and methods of treating rna-mediated diseases | |
PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
CY1124286T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
EA202091655A1 (ru) | Композиции и способы лечения нарушений сетчатки | |
WO2016167944A8 (en) | Compositions and methods for treating autism | |
WO2017059122A8 (en) | Methods of treating and preventing amyotrophic lateral sclerosis |